Objective: To investigate blood oxidative status of patients with chronic renal failure (CRF) and possible effects of hemodialysis on the development of oxidative stress in blood. Materials and Methods: The levels of malondialdehyde (MDA) and oxidation resistance (OR) values were measured in blood plasma, erythrocyte hemolysate and erythrocyte membrane fractions of 33 patients with CRF and of 12 healthy controls. Of the 33 patients, 17 subjects were under hemodialysis treatment. Results: MDA levels were found to be increased in all blood fractions of the patients. OR values were unchanged in erythrocyte hemolysates but decreased in plasma and erythrocyte membrane fractions of the CRF patients. Moreover, erythrocyte MDA levels were determined to be higher in hemodialyzed patients compared with both controls and non-hemodialyzed patients. OR values were lower in all blood fractions of the hemodialyzed patients relative to controls and non-hemodialyzed patients. Conclusion: Results suggest that there is a significant oxidative stress (expressed as peroxidation) in blood samples from patients with CRF, which is further exacerbated by hemodialysis.

Keywords:
Chronic renal failure, Hemodialysis, Oxidative stress
This content is only available via PDF.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.